Hypertension: Epidemiology and cost of illness

Disease Management and Health Outcomes

Volumn 1, Issue 3, 1997, Pages 135-140

  Pardell, Helios ^a,b,c,d,e,f   Armario, Pedro ^a,b   Hernández, Raquel ^a,b   Tresserras, Ricard ^b,c  

^a U Hypertension and Cardiovasc Risk   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c GENERALITAT DE CATALUNYA   (Spain)

^d HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^e CINDI Programme   (Spain)

^f Red Cross Centre   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0040213128     PISSN: 11738790     EISSN: None     Source Type: Journal    
DOI: 10.2165/00115677-199701030-00003     Document Type: Article

References (37)

1. Kaplan NM. Primary hypertension. From pathophysiology to prevention. Arch Intern Med 1996; 156: 1919-20
2. Report of a WHO Expert Committee. Hypertension Control. WHO Technical Report Series, 862. Geneva: World Health Organization, 1996
3. Report of a WHO Espert Committee. Arterial hypertension. WHO Technical Report Series, 628. Geneva: World Health Organization, 1978
4. Pardell H, editor. Arterial hypertension in Spain. 2nd ed. Madrid: Spanish League Against Arterial Hypertension (LELHA), 1986
5. WHO Regional Office for Europe. Study on hypertension control monitoring at community level. Copenhagen: World Health Organization, 1994
6. Spanish Society of Hypertension - Spanish League Against Arterial Hypertension (SEH-LELHA). Control of arterial hypertension in Spain 1996. Madrid: Ministry of Health, 1996
7. Whelton PK. Epidemiology of hypertension. Lancet 1994; 344: 101-6
8. Kannel WB, McGee D, Gordon T. A general cardiovascular risk profile: the Framingham Study. Am J Cardiol 1976; 38: 46-51
9. Kannel WB. Blood pressure as a cardiovascular risk factor. Prevention and treatment. JAMA 1996; 275: 1571-6
10. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease. Part I. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765-74
11. Plans P, Pardell H, Salleras L. Epidemiology of cardiovascular disease risk factors in Catalonia, Spain. Eur J Epidemiol 1993; 9: 381-9
12. Stamler J, Stamler J, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risk: US population data. Arch Intern Med 1993; 153: 598-615
13. Murray CJL, Lopez AD. Evidence-based health policy: lessons from the Global Burden of Disease Study. Science 1996; 274: 740-3
14. Ruilope LM, editor. Present situation of hypertension detection, treatment and control in Spain. Madrid: Spanish League Against Arterial Hypertension (LELHA), 1995
15. Strasser T, Wilhelmsen L, editors. Assessing hypertension control and management. Copenhagen: WHO Regional Office for Europe, 1993
16. World Hypertension League. Hypertension control in our world: agenda for the coming decade. The 1995 WHL Ottawa Declaration. Final statement of the World Conference on Hypertension Control. 1995 June 22-24; Ottawa, Canada
17. Winickoff RN, Murphy PK. The persistent problem of poor blood pressure control. Arch Intern Med 1987; 147: 1393-6
18. Pardell H. Hypertension control, a pending challenge. Hypertension 1995; 12: 255-7
19. Report of a WHO Consultation. Workshop on hypertension control in the community: policy, strategies, monitoring and evaluation. 1994 Feb 27 - Mar 1; Barcelona, Spain. Copenhagen: WHO Regional Office for Europe, 1995
20. Pardell H, Luque M, Aranda P, et al. Therapeutic compliance among hypertensives in Spain. Hypertension 1994; 11: 92-6
21. Haynes RB, Gibson ES, Taylor W, et al. Process versus outcome in hypertension: a positive result. Circulation 1982; 65: 28-33
22. Johannesson M, Jönsson B. A review of cost-effectiveness analyses of hypertension treatment. Pharmacoeconomics 1992; 1: 250-64
23. Thom T. The economic costs of cardiovascular diseases in the United States, 1990. Bethesda (MD): National Heart, Lung, and Blood Institute, 1993
24. Dustan HP, Roccella EJ, Garrison HH. Controlling hypertension. A research success story. Arch Intern Med 1996; 156: 1926-35
25. Schauffer H, D'Agostino R, Kannel WB. Risk for cardiovascular disease in the elderly and associated Medicare costs: The Framingham Study. Am J Prev Med 1993; 9: 146-54
26. Badia X, Rovira J, Tresserras R, et al. The cost of arterial hypertension in Spain. Med Clin (Barc) 1992; 99: 769-73
27. Pardell H, editor. Pharmacoeconomics of arterial hypertension. Madrid: Spanish Society of Hypertension - Spanish League Against Arterial Hypertension (SEH-LELHA), 1996
28. Koopmanschap MA, Rutten FFH. A practical guide for calculating indirect costs of disease. Pharmacoeconomics 1996; 10: 460-6
29. Ménard J, Cornu PH, Day M. Cost of hypertension treatment and the price of health. J Hum Hypertens 1992, 6: 447-58
30. Holloway RG, Witter Jr DM, Lawton KB, et al. Inpatient costs of specific cerebrovascular events at five academic medical centers. Neurology 1996; 46: 854-60
31. Perry Jr HM. Implication of clinical trials. Am J Med 1988, 85: 675-96
32. Pardell H, Armario P, Hernandez R. Progress in the 1980s and new directions in the 1990s with hypertension Management. Drugs 1992, 43: 1-5
33. Lenfant C. High blood pressure. Some answers, new questions and continuing challenges. JAMA 1996; 275: 1604-6
34. Dannenberg AL, Garrison RL, Kannel WB. Incidence of hypertension in the Framingham Study. Am J Public Health 1988; 78: 676-9
35. Pardell H, Tresserras R, Salto E, et al. Economic considerations for joint antihypertension-antismoking programs. Can J Cardiol 1993, 9 Suppl. D: 175D-177D
36. Pardell H, Armario P, Hernandez R, et al. Environmental factors, development of hypertension and opportunities for prevention. J Hypertens 1992; 9: 255-61
37. Fries JF, Koop CE, Beadle CE, et al. Reducing health care costs by reducing the need and demand for medical services. N Engl J Med 1993; 329: 321-5